ClinicalTrials.gg
Not yet recruitingNCT07807501Updated Nov 5, 2026

Meditation Apps for Stress Management in Black Women

An interventional study of Exhale™ Meditation App and Levelhead Mindfulness App in Psychological Stress, sponsored by Arizona State University. Not yet recruiting. Open to female participants aged 35 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Arizona State University · Not applicable, Interventional, and Treatment

Updated Nov 5, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
35 Years to 64 Years
Sex
Female
01

Study summary

This randomized remote pilot study will evaluate the feasibility, acceptability, and preliminary effects of two meditation and mindfulness applications among approximately 40 Black women ages 35-64 experiencing moderate to high stress.

Participants will be randomly assigned in a 1:1 ratio to Exhale™, a culturally adapted meditation app designed for Black women, or Levelhead, a general mindfulness app. Participants will be asked to complete at least one session using their assigned app per day, lasting approximately 5 minutes or longer, at least 5 days per week for 4 weeks.

Participants will complete online questionnaires at baseline and after the 4-week intervention. Daily Remind messages and weekly study check-ins will support engagement. Outcomes include recruitment, retention, adherence, assessment completion, satisfaction, usability, perceived stress, race-based stress, sleep, depression, anxiety, cultural relevance, and brief participant feedback.

Read the detailed description

This study is a two-arm, randomized, fully remote pilot study comparing Exhale™, a culturally adapted meditation application designed for Black women, with Levelhead, a general science-based mindfulness application.

Approximately 40 Black women ages 35-64 who report moderate to high perceived stress will be enrolled. After eligibility screening, informed consent, and completion of baseline questionnaires through REDCap, participants will be randomized in a 1:1 ratio to Exhale™ or Levelhead using the REDCap randomization module.

Participants in both groups will be asked to complete at least one app-based meditation or mindfulness session per day, lasting approximately 5 minutes or longer, at least 5 days per week for 4 weeks. Participants may complete additional or longer sessions but will not be required to make up missed sessions. Daily Remind messages will ask participants whether they completed a session and the approximate number of minutes practiced. Weekly check-ins will provide study reminders and opportunities to request technical assistance.

Remote questionnaires will be administered at baseline and at the end of Week 4. Primary outcomes will assess feasibility and acceptability through recruitment, retention, adherence, assessment completion, satisfaction, and usability. Secondary outcomes will examine preliminary changes in perceived stress, race-based stress, sleep, depression, and anxiety. Cultural relevance and brief open-ended participant feedback will also be collected. Some participants may be invited to complete an optional brief remote exit interview.

02

Conditions studied

  • Psychological Stress

Browse trials for

Keywords

  • Black women
  • African American women
  • meditation
  • mindfulness
  • mobile health
  • digital health
  • culturally adapted intervention
  • race-based stresss
  • stress management
  • feasibility
  • acceptibility
03

In context

Stress, Psychological

844 studies on the registry are indexed under Stress, Psychological; 136 are open to participants now.

This study's planned enrollment of 40 is below the median of 84 across 688 interventional studies indexed under Stress, Psychological.

Browse Stress, Psychological studies →

Lead sponsor

Arizona State University is the lead sponsor of 238 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 64 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Self-identifies as a Black or African American woman
  • Ages 35-64 years
  • Able to read and speak English
  • Perceived Stress Scale-10 screening score greater than 14
  • Has access to a smartphone or tablet with internet access
  • Willing to complete remote baseline and post-intervention assessments
  • Willing to attempt the assigned app-based practice for 4 weeks
  • Willing to receive study communications

Exclusion criteria

Exclusion Criteria:

  • Regular use of meditation or mindfulness applications within the previous 6 months
  • Any prior use of Exhale™
  • Significant hearing impairment that prevents engagement with audio-based application content
  • Self-reported difficulty navigating smartphone applications that would prevent participation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Exhale™ Meditation App

    Participants assigned to Exhale™ will use a culturally adapted meditation application designed for Black women. Participants will be asked to complete at least one meditation session per day, lasting approximately 5 minutes or longer, at least 5 days per week for 4 weeks. Participants will receive daily Remind messages, weekly study check-ins, and remote technical support as needed.

    Behavioral: Exhale™ Meditation App

  • Active comparator
    Levelhead Mindfulness App

    Participants assigned to Levelhead will use a general science-based mindfulness application. Participants will be asked to complete at least one mindfulness session per day, totaling approximately 5 minutes or longer, at least 5 days per week for 4 weeks. Participants will receive daily Remind messages, weekly study check-ins, and remote technical support as needed.

    Behavioral: Levelhead Mindfulness App

Interventions

  • BehavioralExhale™ Meditation App

    A culturally adapted meditation application designed for Black women that provides guided meditation and mindfulness content addressing stress, rest, grounding, self-care, and culturally relevant experiences. Participants will manually select sessions and complete approximately 5 minutes or longer of practice at least 5 days per week for 4 weeks.

  • BehavioralLevelhead Mindfulness App

    A general science-based mindfulness application that provides brief lessons addressing topics such as stress, focus, gratitude, and well-being. Participants will complete approximately 5 minutes or longer of mindfulness practice at least 5 days per week for 4 weeks.

06

What researchers measure

Primary outcomes

  1. Participant Retention Rate at Week 4

    Percentage of enrolled participants who complete the 4-week intervention and post-intervention assessment. The feasibility benchmark is greater than 75%.

    Time frame: Baseline through Week 4

  2. Percentage of Eligible Individuals Who Consent and Enroll

    Recruitment rate will equal the number of eligible individuals who consent and enroll divided by the total number determined eligible, multiplied by 100. The feasibility benchmark is greater than 70%.

    Time frame: From recruitment opening through enrollment of the final participant, up to 6 months.

  3. Percentage of Recommended Practice Days Completed

    Adherence will be calculated from participant self-reports as completed practice days divided by 20 recommended practice days, multiplied by 100. The benchmark is greater than 75%.

    Time frame: During the 4-week intervention

  4. Assessment Completion Rate

    Percentage of expected baseline and post-intervention questionnaires completed by enrolled participants. The benchmark is greater than 75%.

    Time frame: Baseline and Week 4

  5. Participant Satisfaction With Assigned App

    Satisfaction will be measured with the assigned-app satisfaction questionnaire. Items are rated from 1 to 5, with higher scores indicating greater satisfaction. Results will be summarized overall and by intervention arm.

    Time frame: Week 4

  6. Assigned-App Usability Measured by the System Usability Scale

    The 10-item System Usability Scale produces a total score from 0 to 100. Higher scores indicate better perceived usability.

    Time frame: Week 4

Secondary outcomes

  1. Change in Perceived Stress Scale-10 Score

    The PSS-10 contains 10 items and produces a total score from 0 to 40. Higher scores indicate greater perceived stress. Change from baseline will be reported overall and by arm.

    Time frame: Baseline to Week 4

  2. Change in Index of Race-Related Stress-Brief Score

    The 22-item IRRS-B produces a total score from 0 to 88. Higher scores indicate greater race-related stress. Change from baseline will be reported overall and by arm.

    Time frame: Baseline to Week 4

  3. Change in POMS-SF Depression Subscale Score

    The six-item depression subscale produces a score from 0 to 24. Higher scores indicate greater depressive mood disturbance.

    Time frame: Baseline to Week 4

  4. Change in POMS-SF Tension/Anxiety Subscale Score

    The six-item tension/anxiety subscale produces a score from 0 to 24. Higher scores indicate greater tension or anxiety.

    Time frame: Baseline to Week 4

  5. Change in Insomnia Severity Index Score

    The seven-item Insomnia Severity Index produces a total score from 0 to 28. Higher scores indicate more severe insomnia symptoms.

    Time frame: Baseline to Week 4

Other outcomes

  1. Participant-Reported Cultural Relevance and App Feedback

    Cultural relevance, perceived usefulness, barriers, benefits, and recommendations will be assessed through post-intervention items and brief open-ended feedback. Optional remote interviews may provide additional qualitative feedback.

    Time frame: Week 4 and, when applicable, within approximately 1 week after Week 4

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available. Aggregate or de-identified summary findings may be disseminated through presentations, publications, or participant summaries. Any future sharing of de-identified participant data would require additional institutional review and must be consistent with the informed consent form and Arizona State University requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

Of 457 non-industry interventional studies with no phase under Stress, Psychological, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 4 months is below that.

Counting every sponsor, half of 470 studies reached it within 13 months; a quarter within 5 and three quarters within 26.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Sep 2026 → Nov 2026, primary completion Jan 2027 → Mar 2027 and completion Jan 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 8, 2026
StartEst.
Nov 16, 2026was Sep 2026
Primary completionEst.
Mar 2027was Jan 2027
CompletionEst.
May 2027was Jan 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 16, 2026→Nov 16, 2026
Nov 5, 2026
Primary completion
Jan 2027→Mar 2027
Nov 5, 2026
Study completion
Jan 2027→May 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Start date Sep 16, 2026→Nov 16, 2026
    Primary completion Jan 2027→Mar 2027
    Study completion Jan 2027→May 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07807501
Responsible party
Sunny Wonsun Kim, Ph.D (Associate Professor, Arizona State University) — Principal investigator
First posted
Sep 8, 2026
Start date
Nov 16, 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Sunny Kim, PhD
Contact
sunny.kim@asu.edu
602-496-6789

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion